Physician profile
Demetrius Rizos
NPI 1063491397
$1,262.30
in general payments reported to CMS, 2019-2025
22 companies · $21.69 in 2025
The $21.69 reported for 2025 was less than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,069 · 2020: $157 · 2023: $14.75 · 2025: $21.69.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $36.44.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $36.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $200.86 | 2019 | |
| Pfizer INC. | $189.69 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $157.76 | 2019-2020 | |
| Amgen INC. | $131.11 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $78.19 | 2019 | |
| Lilly USA, LLC | $76.23 | 2019 | |
| Novo Nordisk INC | $74.34 | 2019-2020 | |
| Astellas Pharma US INC | $63.96 | 2019 | |
| Glaxosmithkline, LLC. | $62.52 | 2019 | |
| Astrazeneca Pharmaceuticals Lp | $58.88 | 2019 | |
| Shire North American Group INC | $23.75 | 2019 | |
| Sanofi-Aventis U.S. LLC | $22.80 | 2019 | |
| Ardelyx, INC. | $21.69 | 2025 | Ibsrela |
| E.R. Squibb & Sons, L.L.C. | $20.97 | 2020 | |
| Bardy Diagnostics, INC. | $20.00 | 2020 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amarin Pharma, INC. | $17.95 | 2019 | |
| Abbvie INC. | $14.75 | 2023 | Teflaro, Dalvance |
| Metuchen Pharmaceuticals | $13.72 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $13.13 | 2020 |
3 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Demetrius Rizos listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.